The European Commission (EC) has granted marketing authorization for Meda's Zyclara (imiquimod 3.75% cream) for the treatment of actinic keratosis (AK), in the European Union.
Zyclara can detect and eliminate subclinical as well as clinical AK lesions on large areas of the skin.
Zyclara has shown to be an effective therapy in eliminating both kinds of AK lesions and with low recurrence rate in a large clinical development program.
Meda CEO Anders Lonner said, "Skin cancer is increasing and it is important to develop and improve the treatment of actinic keratosis. Zyclara is unique since it can treat large areas of the skin."
AK, early skin carcinoma in situ is an under-diagnosed and under-treated disease. There exists a close regional coexistence of invisible (subclinical AK lesions) as well as clinical visible AK lesions on areas of sun exposed skin, a phenomenon which is called field cancerization.
